top of page

Osteosarcoma Treatment in China: Options and Specialist Hospitals

By

ChinaCureLink

Wed Nov 18 2026

10 min read

4 hours ago
10 min read

Medically reviewed by Dr Eric Wang- ChinaCureLink Team


Bone cancer (osteosarcoma) treatment in China usually combines chemotherapy with surgery for conventional high-grade disease. The first step is review by a specialist bone-sarcoma team that can plan the biopsy, stage the cancer and assess safe removal. Limb-sparing surgery may be possible, but the aim is adequate cancer removal and useful function; it cannot be promised for every tumor.


This guide is for international patients and families considering care in China. It explains established treatment, recent Chinese research, three hospital options and six bone-tumor specialists. Osteosarcoma is a primary bone cancer: it is different from cancer that has spread to bone from another organ, and from other bone sarcomas such as Ewing sarcoma. Those diagnoses require different treatment discussions.


Key Takeaways

  1. Confirm the exact pathology and stage before choosing a treatment; conventional high-grade osteosarcoma usually needs chemotherapy and surgery.

  2. A specialist should plan the biopsy with the later operation in mind. An unplanned procedure can affect surgical options.

  3. Limb salvage depends on safe tumor removal and reconstruction; preserving a limb does not always preserve normal function.

  4. A Chinese randomized phase II trial improved progression-free survival in relapsed disease but did not show an overall-survival benefit.

  5. ChinaCureLink matching is free. Specialist video opinions are paid, with fees confirmed before booking; treatment access and suitability require clinical assessment.


Table of Contents


Established Treatment Starts With a Sarcoma Team


A suspected primary bone tumor needs a coordinated diagnostic plan. Imaging should precede biopsy, and the biopsy route should be agreed with the team that may remove the tumor. Send existing scans and pathology for review rather than arranging a new biopsy or definitive operation independently of the receiving sarcoma service.


For conventional high-grade osteosarcoma, treatment commonly includes chemotherapy before surgery, removal of the tumor and further chemotherapy afterward. Regimens may include methotrexate, doxorubicin and cisplatin, with selection and monitoring adapted to age, organ function and the treating protocol. Selected low-grade osteosarcomas may be managed differently.


Limb-sparing surgery removes the tumor while reconstructing the remaining bone or joint where feasible. Amputation may be recommended when safe margins or useful reconstruction cannot be achieved. A custom implant or 3D-printed device addresses a reconstruction problem; it does not replace chemotherapy or prove better cancer survival.


When cancer has spread or returned, the team should assess whether all disease can be removed and how systemic treatment fits the plan. Radiotherapy has selected roles when surgery is not feasible or for symptom control, rather than being the usual replacement for surgery in resectable conventional osteosarcoma.


On a smaller screen, swipe the table horizontally to view every column.


Clinical Situation

Treatment Discussion

What Changes the Plan

Localized high-grade osteosarcoma

Chemotherapy and complete surgical removal, with an individualized reconstruction plan

Tumor location, resectability, health status and response to chemotherapy

Metastatic disease at diagnosis

Systemic treatment and assessment of whether the primary tumor and metastases can be completely removed

Number and location of lesions, response and feasibility of surgery

Recurrent or refractory disease

Review further surgery, chemotherapy, selected targeted approaches or clinical trials

Prior medicines, disease distribution, organ function and the goal of treatment


Chinese Research in Relapsed Osteosarcoma


A November 2025 Chinese randomized phase II trial enrolled 81 patients whose osteosarcoma had progressed after chemotherapy. It compared apatinib plus ifosfamide/etoposide with ifosfamide/etoposide alone. Chemotherapy lasted three days per cycle in the combination arm versus five in the control arm.


At median follow-up of 19.9 months, median progression-free survival was 5.5 versus 3.4 months. Overall survival was not significantly improved: medians were 18.1 versus 22.9 months. Grade 3 or higher treatment-related adverse events occurred in 69.8% versus 64.3%.


This exploratory result needs phase III confirmation and does not establish a new first-line standard. Discuss alternatives, toxicity monitoring and whether a proposal is approved, off-label or investigational. Publication does not establish trial recruitment or access.


Evidence

Reported Finding

Practical Limit

Chinese randomized phase II study; 81 previously treated patients

Median progression-free survival: 5.5 vs 3.4 months

Exploratory result; chemotherapy schedules differed and phase III confirmation is needed

Survival and safety in the same study

No significant overall-survival improvement; grade 3+ treatment-related events: 69.8% vs 64.3%

A delay in progression is not proof of longer life; severe toxicity remained common


Which Treatment Fits Your Diagnosis?

Eligibility depends on condition, medical history and treatment goals. Send your records and we’ll match you with relevant Chinese hospitals and specialists at no cost.

Free matching · Paid video specialist consultations · Fees confirmed before booking


Planning an Assessment From Overseas


Prepare the biopsy report, slides or blocks where requested, original MRI and other imaging in DICOM format, chest imaging, staging reports, operation notes and the complete chemotherapy record. Include doses and dates, response assessments, complications and recent blood, kidney, liver and heart assessments where available. The receiving team will specify what needs updating or translation.


For a child or teenager, confirm that the service can provide age-appropriate oncology, anesthesia, rehabilitation and continuing growth assessment. Ask how a reconstruction may affect future limb length, joint function and the need for revision. Discuss fertility preservation and treatment-related heart, hearing or kidney risks before the relevant medicines are started.


Obtain written confirmation of the receiving clinician, department, campus, interpretation and treatment sequence. Ask which parts can be planned from records and which need examination or further investigations in China. Avoid treating an inquiry, tentative clinic date or proposed operation as confirmed clinical acceptance.


Request an itemized estimate covering pathology review, staging, chemotherapy, admission, surgery, implant or graft, rehabilitation and follow-up. A custom implant is not a complete cancer-treatment package. Confirm potential additional charges, deposits and insurance requirements. Our medical trip planning guide and China medical tourism guide cover the wider preparation.


How ChinaCureLink Helps You Compare Appropriate Teams


ChinaCureLink helps organize the diagnosis, stage, imaging and treatment history for specialist assessment and matches the case with up to three appropriate hospitals or specialists. For osteosarcoma, the useful comparison includes bone-tumor surgery, systemic treatment, pathology and rehabilitation, rather than a hospital name or implant alone. The treating team makes the clinical recommendation.


Hospital and specialist matching is free. Optional specialist video second opinions are paid, with fees confirmed before booking. Later coordination may include appointments, records, interpretation arrangements, travel and follow-up; confirm scope and cost in writing. The hospital and specialist matching guide explains the process.


Three Hospitals and Six Bone-Tumor Specialists


Beijing Jishuitan Hospital, Sun Yat-sen University Cancer Center and West China Hospital have documented bone and soft-tissue tumor services. This is a service-based comparison, not an osteosarcoma survival ranking. The China hospital comparison guide explains broader selection criteria.


The profiles illustrate relevant clinical interests. The hospital must confirm the appropriate clinician, age group, campus and availability. Consultation buttons send an inquiry and do not establish an appointment or guarantee that a particular doctor will perform surgery.


1. Beijing Jishuitan Hospital


Beijing Jishuitan Hospital was founded in 1956. Its bone-tumor work developed into a separate professional group in 1977 and an independent department in 1984. A bone and soft-tissue tumor diagnosis and research center was established in 2021.


For osteosarcoma, the relevant feature is specialist planning across diagnosis, chemotherapy and tumor removal, with reconstruction considered in relation to safe margins and expected function. The institution’s documented work includes bone-tumor surgery, treatment research and multidisciplinary collaboration.


The photo shows the Xinlongze campus. Confirm the actual receiving campus, clinic and treatment locations, because a hospital with several sites may distribute consultations, surgery and other services across them. Ask how the proposed plan will connect cancer treatment with rehabilitation and later surveillance.



Beijing · Multiple Campuses · Confirm Bone-Tumor Clinic · Public Teaching Hospital · Specialist Bone-Tumor Services


Bone and soft-tissue tumors · Limb-salvage assessment · Reconstruction


Known for: A long-established orthopedic oncology service with a dedicated bone and soft-tissue tumor center.



2. Sun Yat-sen University Cancer Center


Established in 1964, Sun Yat-sen University Cancer Center combines specialist cancer care, research and education. Its bone and soft-tissue tumor department describes collaboration with medical oncology, radiotherapy, imaging and pathology in a sarcoma multidisciplinary model.


Its published specialist profiles explicitly include comprehensive osteosarcoma care, limb-salvage surgery and complex bone or pelvic reconstruction. This combination is relevant when a family needs a coordinated opinion on the timing of chemotherapy, tumor removal and rehabilitation.


The center operates across Guangzhou campuses, and the photograph shows Huangpu. Confirm which location provides the receiving specialist and each part of treatment. A custom reconstruction should be considered as one part of an overall cancer plan, with realistic discussion of function and possible future procedures.



Guangzhou · Yuexiu and Huangpu · Confirm Campus · Public Specialist Cancer Hospital


Osteosarcoma assessment · Bone and soft-tissue surgery · Sarcoma multidisciplinary care


Known for: A dedicated cancer setting linking bone-tumor surgery with other sarcoma services.



3. West China Hospital, Sichuan University


West China Hospital traces its history to 1892. Its bone-tumor professional group developed within orthopedics from 1984, and the institution established a bone and soft-tissue tumor center in 2012. The wider hospital provides other specialist services when illness or treatment complications require them.


The center documents limb-salvage surgery, bone and joint reconstruction, custom prostheses and research in bone-tumor treatment. These services are relevant to comparing how a team will remove the tumor and address the resulting defect, rather than choosing a device without a complete clinical plan.


Ask how surgical and systemic-treatment assessments are coordinated and what rehabilitation and implant follow-up will require. For children, confirm the appropriate pediatric oncology and growth-related expertise. Published technical experience does not establish a result for an individual patient or routine access to a research regimen.



Chengdu · Confirm Receiving Bone-Tumor Service · Public University General Hospital


Bone and soft-tissue tumor center · Limb reconstruction · Comprehensive hospital support


Known for: A dedicated bone-tumor center within a comprehensive university hospital.



A Recent Reconstruction Case and the Long-Term Lesson


A 2026 Chinese case report described a 28-year-old man treated for distal-femoral osteosarcoma in childhood with a tumor knee prosthesis. Years later, a fall caused a femoral-neck fracture, while the existing distal implant remained stable. The team used a custom reconstruction designed to preserve that stable component.


The authors reported functional improvement over approximately six months, with the Harris Hip Score increasing from 63 at three months to 81 at about six months. This was reconstruction after a late complication in a survivor, not treatment of active osteosarcoma or evidence of a new cancer cure. It was one patient with short follow-up for assessing implant durability.


The practical lesson is to plan beyond the initial operation. Children and young adults may need years of monitoring for growth, limb-length differences, implant problems and function, alongside cancer surveillance. Custom reconstruction can help a selected mechanical problem, but revision procedures and long-term support may still be necessary.


Continuing Cancer Surveillance and Rehabilitation


Before returning home, agree who will provide cancer surveillance, chemotherapy monitoring where needed, wound and implant checks, rehabilitation and growth assessment. Obtain a written activity and weight-bearing plan from the surgical team; restrictions depend on the operation and reconstruction.


Collect the final pathology, surgical-margin and treatment-response reports, imaging, chemotherapy summary and implant details. Ask how the Chinese team will share information with your local sarcoma service and what symptoms require urgent assessment. Continuing care should be planned before travel, particularly when chemotherapy and surgery occur in different countries.


You Contact the Hospital vs. via ChinaCureLink


Both routes can work. Many large Chinese hospitals have international departments, and some patients go direct. Here is what each route looks like, step by step.


Swipe the table horizontally on smaller screens to view all columns.

What to Arrange

Contacting Hospitals Yourself

With ChinaCureLink

Hospital and specialist choice

Research and contact suitable teams yourself

✓ Diagnosis-based hospital and specialist matching — free

Appointments

Arrange times and follow up with each team

✓ Support with scheduling and hospital communication

Medical records

Prepare and translate the required documents

✓ Help organizing records for specialist review

Language assistance

Check the hospital’s interpreter arrangements

✓ Help arranging interpretation for medical discussions

Travel and accommodation

Book your travel and stay independently

✓ Coordination after you choose to proceed

Local coordination

Check what support the hospital offers

✓ Coordinator support during your stay

Continuing care

Request records and arrange follow-up yourself

✓ Help coordinating records for your home doctor

Hospital quote

Ask the hospital for an itemized estimate

✓ Help obtaining the quote and applying for an international discount, where available


Hospital and specialist matching is free. Specialist video consultations and later on-site services have separate fees, confirmed before booking. Any hospital discount depends on the hospital and individual quotation.


Start With Free Hospital and Specialist Matching

ChinaCureLink represents patients, not hospitals. Hospital and specialist matching is free, and travel coordination begins only after you choose to proceed.

Free matching · Paid video specialist consultations · Fees confirmed before booking


Next step: Obtain a diagnosis-matched assessment, compare the written recommendations and confirm costs and follow-up before making travel arrangements.


Get a Second Opinion


For suitable cases, ChinaCureLink can then coordinate an online consultation with the specialist to discuss the technical treatment details directly. The purpose is to help the patient understand which treatment option and which specialist center may be most appropriate before making an international treatment decision.


Hospital and specialist matching is free. Video second opinions are paid specialist consultations, with fees confirmed before booking.




What Patients Say About ChinaCureLink & Medebound HEALTH


Medebound HEALTH company and patient feedback — bone cancer (osteosarcoma) treatment in China guide

China CureLink operates under Medebound HEALTH — an internationally recognized healthcare navigation company incorporated in New York, with operations across North America and Asia-Pacific.



Frequently Asked Questions


What is the usual treatment for osteosarcoma in China?

Conventional high-grade osteosarcoma usually requires chemotherapy and complete surgical removal, with treatment before and after surgery according to the clinical plan. Selected low-grade tumors may be managed differently. A specialist sarcoma team should confirm pathology, stage, resectability and age-appropriate care before treatment.


Can osteosarcoma be treated with limb-salvage surgery?

Limb salvage may be possible when the tumor can be removed safely and the remaining limb reconstructed with useful function. Tumor location, involved structures, treatment response and other factors affect suitability. Amputation may be recommended in some cases, and a custom implant does not guarantee limb preservation or normal function.


Are targeted therapies or clinical trials available for recurrent osteosarcoma in China?

Chinese studies have investigated targeted medicines and combinations after chemotherapy failure, but research findings do not establish suitability or access. The receiving team must check prior treatment, disease distribution, organ function, regulatory status and current trial recruitment for the specific proposal.


Talk It Through Before You Decide

Start with free hospital and specialist matching. We’ll review your situation and match you with relevant hospitals and specialists at no cost. Paid video second opinions are available, with fees confirmed before booking.

Free matching · Paid video specialist consultations · Fees confirmed before booking



About ChinaCureLink


ChinaCureLink helps patients across the world access the best cancer treatment at China's top hospitals, without the delays, language barriers, and administrative confusion that typically come with seeking care abroad.


We connect patients directly with China's top cancer hospitals, ensuring that from the first case submission through to treatment and follow-up, every step is guided, translated, and coordinated by a team experienced in cross-border patient care.


ChinaCureLink is proudly affiliated with Medebound HEALTH — founded by US physicians, with over 10 years of experience and more than 3,000 patients served worldwide, Medebound HEALTH is recognized by Forbes and it is one of the most trusted patient cross-border concierge service company across North America and the Asia Pacific.


References



Disclaimer


This article is for informational purposes only and is not medical or financial advice. Treatment eligibility, protocols, and costs vary by individual case — confirm specifics with a coordinator and treating physician before making any decisions.


You may also like:



bottom of page